- 专利标题: Anti-ICOS agonist antibodies and uses thereof
-
申请号: US15946625申请日: 2018-04-05
-
公开(公告)号: US10898556B2公开(公告)日: 2021-01-26
- 发明人: John J. Engelhardt , Mark J. Selby , Alan J. Korman , Mary Diane Feingersh , Brenda L. Stevens
- 申请人: BRISTOL-MYERS SQUIBB COMPANY
- 申请人地址: US NJ Princeton
- 专利权人: BRISTOL-MYERS SQUIBB COMPANY
- 当前专利权人: BRISTOL-MYERS SQUIBB COMPANY
- 当前专利权人地址: US NJ Princeton
- 代理机构: Nelson Mullins Riley & Scarborough LLP
- 代理商 Jane E. Remillard, Esq.; Jeanne M. DiGiorgio, Esq.
- 主分类号: C07K16/28
- IPC分类号: C07K16/28 ; A61K39/395 ; A61K39/00 ; A61P35/00
摘要:
The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.
公开/授权文献
- US20180289790A1 ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF 公开/授权日:2018-10-11
信息查询